Title
Thrombocytopenia Induced by Chemotherapy
A Post Marketing Randomized Placebo Controlled Study to Evaluate the Efficacy of Study Product UPLAT® (Carica Papaya Leaf Extract + Tinospora Cardifolia Extract) in the Cancer Patients With Thrombocytopenia Induced by Chemotherapy
Phase
N/ALead Sponsor
Socrates School Of HealthStudy Type
InterventionalStatus
Completed No Results PostedIndication/Condition
ThrombocytopeniaIntervention/Treatment
uplat ...Study Participants
60Single blind, randomized, multicentric placebo controlled study to evaluate the efficacy of Study product in patient with Chemotherapy induced thrombocytopenia. The Study is divided into [screening visit (visit 1) > baseline and treatment allocation visit (visit 2) >blood collection (visit 3); treatment compliance visit (visit 4) > blood collection (visit 5) >blood collection (visit 6)>end of study visit (visit 7)].
UPLAT® (Carica papaya leaf Extract + Tinospora cardifolia Extract), is an orally administered dietary supplement for management of thrombocytopenia. Manufactured bySanat Products Ltd.
Throughout study, it will be designated as product A to maintain study blindness at subject end.
Placebo Throughout study, it will be designated as product B to maintain study blindness at subject end.
Single blind, randomized, multicentric placebo controlled study to evaluate the efficacy of Study product in patient with Chemotherapy induced thrombocytopenia. The Study is divided into [screening visit (visit 1) > baseline and treatment allocation visit (visit 2) >blood collection (visit 3); treatment compliance visit (visit 4) > blood collection (visit 5) >blood collection (visit 6)>end of study visit (visit 7)].
Dose regimen After meeting the inclusion criteria subject will take 4 units daily (2 in morning and 2 in evening) for 10 days. Patients will be called on Day5th, 10th and 15thfor the Complete blood count (Central lab).
Total blood loss Approximately 8-12 mL
Carica papaya leaf Extract + Tinospora cardifolia Extract
Placebo
Inclusion Criteria: Male or female aged between 18-55 years. Subjects must sign with date an informed consent prior to any evaluation and participation in the trial. Patients who were confirmed solid tumour and received at least one cycle of chemotherapy prior to screening visit. Patients with a platelet counts between > 20000 and < 150,000/ml at the time of screening. Exclusion Criteria: Planning to receive any type of surgery. Pregnant or lactating women. Patients with platelet count less than 20000/ml. Patients with thrombocytopenia presenting with active bleeding. Patients who have received blood or blood product transfusion during the current illness or during past one week. Patients with thrombocytopenia purpura (ITP) leukemia, hemophilia or bleeding diathesis. Participation in another trial with another investigational product